

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



瑋俊 生 物 科 技 有 限 公 司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

INSIDE INFORMATION WITHDRAWAL OF WINDING UP PETITION

This announcement is made by Wai Chun Bio-Technology Limited (the “**Company**”) pursuant to Rules 13.09(2) and 13.25(1)(b) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated 25 October 2023 and 27 October 2023 regarding the winding up petition against the Company (the “**Announcements**”). Unless the context otherwise specified, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

The Board hereby announces that a settlement has been reached, without admission of liability, on 28 November 2023 between the Company and the Petitioner in relation to the Petition (the “**Settlement**”). Following the Settlement, a consent summons for the withdrawal of the Petition was executed and filed with the High Court of Hong Kong on 4 December 2023, and the High Court of Hong Kong has ordered that the Petition be withdrawn on 6 December 2023.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Wai Chun Bio-Technology Limited
LAM KA CHUN
Chairman and Chief Executive Officer

Hong Kong, 8 December 2023

As at the date of this announcement, the Board consists of one executive Director, namely Mr. Lam Ka Chun and two independent non-executive Directors, namely Ms. Hong Ting and Mr. Wan Bo.